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The current high life expectancy is overshadowed by neurodegenerative illnesses that lead to
dementia and dependence. Alzheimer’s disease (AD) is the most common of these conditions,
and is considered to be a proteinopathy, with amyloid-b42 as a key factor, leading via a
cascade of events to neurodegeneration. Major factors involved are oxidative stress, perturbed
Ca homeostasis and impaired energy metabolism. Protection against oxidative stress by
micronutrients (including secondary bioactive substances) has been shown in transgenic
Alzheimer model systems to delay AD. Epidemiological evidence is less conclusive, but the
vast majority of the evidence supports a protective effect on cognitive functions in old age and
AD. Thus, a diet rich in fruits and vegetables but also containing meat and fish is the most
suitable to provide adequate micronutrients. The strong link between cardiovascular risk and
AD may be explained by common pathogenetic mechanisms mediated, for example, by
homocysteine and thus dependant on B-vitamins (folate and vitamins B12 and B6). However,
micronutrients may also be harmful. The high affinity of amyloid for metals (Fe, Al and Zn)
favours the generation of reactive oxygen species and triggers an inflammatory response.
Micronutrients in a balanced diet have a long-lasting, albeit low, protective impact on brain
aging, hence prevention should be life long.
Alzheimer’s disease: Oxidative stress: Cognitive function
Dementia, and thus its major cause Alzheimer’s disease
(AD), has become one of the major health challenges of
the 21st century in industrialized societies. Prevalence
studies (Jorm & Jolley, 1998) and incidence studies (The
Canadian Study of Health and Aging Working Group,
2000) consistently show a single exponential increase with
age, which is consistent with involvement of a large num-
ber of complex genetic and environmental interactions.
Among these factors, nutrition, intimately linked to aging,
plays an important role. However, despite the strong
age-related link, AD is not an inevitable consequence of a
long life. The incidence levels at age 90 years and in cen-
tenarians indicate that many individuals in this age-group
are barely affected by AD (Ritchie & Lovestone, 2002).
The present review explores the extent to which micro-
nutrients may influence the onset of AD and related
dementias either by preventing or delaying the disease or
by fuelling the pathology.
The clinical diagnosis of AD is characterized by a
progressive deterioration of memory, as well as other
cognitive functions, and impairment of affective and
emotional control, resulting in disability in daily living and
loss of autonomy. Neuropathology remains the diagnostic
gold standard, characterized by deposits of amyloid-b
(abeta; a fragment of the large amyloid precursor protein
(APP)) in plaques and in vessel walls and aggregated tau-
proteins in tangles, reactive micgrogliosis and astrocytosis,
leading to neuronal death with subsequent atrophy of the
brain and enlargement of the ventricles. One of the first
events is the loss of synapses, leading to neuronal dys-
function (Lovestone & McLoughlin, 2002). The eluci-
dation of the mechanism leading to the hallmarks of AD,
i.e. the loss of synapses, the formation of amyloid plaques
and fibrillary tangles, should yield valuable hypotheses on
how nutrients, lifestyle factors or drugs might modify this
otherwise largely intrinsic process linked to aging.
The pathological cascade is apparently triggered in sus-
ceptible individuals many years before clinical symptoms
emerge. Thus, environmental factors and nutrients may
play an important role early in the life cycle (Fig. 1). The
late onset of the disease further indicates that genetic
controls diminish with advancing age and the impact of
external factors becomes more prominent. However, the
similar prevalence and incidence over a wide range of
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dietary habits and social settings in different societies, at
least in the industrialized world, suggests that diet and
nutritional habits may only have a small effect on the
manifestation of the disease. Furthermore, the epidemi-
ology of AD supports the notion that the response of the
aging brain to accumulating stress of endogenous origin,
such as free radicals generated during mitochondrial
energy production (Turner & Schapira, 2001; Aliev et al.
2002) and by exogenous factors, is non-specific. Thus, the
question arises as to how micronutrients affect these pro-
cesses. Micronutrients are essential for growth and func-
tion, and their metabolic effects were elucidated during the
last century by investigating deficiency states. In this con-
text deficiency of I, leading to goitre and cretinism, and
also deficiencies of some vitamins were found to affect
brain function. Subsequently, the regulatory agencies set
the recommended dietary intake at a level sufficient to
prevent signs and symptoms related to deficiency. There is
evidence that higher intakes of certain micronutrients may
be beneficial in reducing the risk of AD (Bates et al. 2002).
Oxidative stress and antioxidants in
Alzheimer’s disease
Oxidative stress is thought to be an early event in AD, and
also to be increased by the disease process in a vicious
circle. As a consequence, antioxidant defence should retard
or even prevent the development of the disease. Brain
metabolism requires a high and constant energy supply by
mitochondria, leading to a constant load of free radical
formation (Aliev et al. 2002; Engelhart et al. 2002b; Cutler
et al. 2004), which suggests that a high antioxidant intake
as nutrients in food and beverages might be protective
(Joseph et al. 1996).
However, several mechanisms seem to interact. Thus,
insulin seems to improve the energy supply to the brain
and enhance brain function. However, high glucose levels
and hyperinsulinaemia indicate insulin resistance and the
formation of advanced glycation end products that by itself
contributes to radical formation, with detrimental con-
sequences to nerve cells and blood vessels (White, 2003).
On the other hand, the defence mechanism may be directly
related to nutrients, or the nutrients may exert their influ-
ence indirectly. For example, there is an increased risk of
AD in the presence of vascular risk factors, leading to
hypoxia, oxidative stress and neuronal damage (Hofman
et al. 1997; Seshadri et al. 2002). Another example is folic
acid, vitamin B12 and vitamin B6, which affect homo-
cysteine metabolism and indirectly influence oxidative
stress, but also protect DNA against reactive oxygen
species and radiation damage by methylation (Fenech,
2001). It has been observed (Fusek, 2001) that parenteral
substitution of low vitamin B12 levels (<180 pmol/l) is
associated with a markedly better cognitive performance in
AD-patients after 1 year, but only if the substitution
occurs within 24 months after the onset of the first
symptoms.
Epidemiological evidence suggests that a high intake
of antioxidants in food correlates with a lower incidence of
cognitive decline (Gray et al. 2003). For antioxidants
nutrients, particularly vitamins C and E but also caro-
tenoids such as lycopene, epidemiological studies (Haller
et al. 1996; La Rue et al. 1997; Masaki et al. 2000) have
shown correlations between intakes, plasma levels and
cognitive function. On the other hand, the findings of
intervention studies of the effect of antioxidants in patients
with AD (Rutten et al. 2002; Gilgun-Sherki et al. 2003)
have been mostly disappointing. One explanation may be
that the effect of altering one antioxidant has no substantial
impact on the cellular redox system, or that the interven-
tion is too late to be of clinical significance.
Plasma antioxidant levels have been shown to predict
memory performance over a 20-year period in the
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Fig. 1. Structural damage leading to functional impairment and ultimately to neuronal death is influenced by many components at different
levels, some of which are protective and some are damaging. Opportunities for interventions arise from preventing associated illnesses as
well as by direct effects via nutrients on the cascade of pathological events such as amyloid-b; ROS, reactive oxygen species; tau-hyperphos,
tau-hyperphosphorylation, SNP, single-nucleotide polymorphisms.
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Basel Study (Perrig et al. 1997; Fig. 2) and also in the
unrelated cross-sectional SENECA study (Haller et al.
1996), in which higher plasma levels were found to be
associated with better memory performance. However,
epidemiological surveys have provided a mixed picture.
In the Rotterdam Study (Engelhart et al. 2002b) lower risk
of AD was found to be associated with high intakes of
vitamin E and C, and also b-carotene and flavonoids in
smokers, in a 6-year follow-up, while vitamins E and C in
the diet or as supplements were found to have no effect on
cognition in the Washington Heights-Inwood Columbia
Aging Project 4-year follow-up (Luchsinger et al. 2002).
On the other hand, the intakes of vitamin C and E sup-
plements have been reported to be associated with lower
incidence of AD (4.3 years follow-up; Morris et al. 1998).
However, the provision of supplements remains con-
troversial. It has been observed that vitamin E appears to
be protective when derived from the diet but not when
provided as a supplement, and then only in apoE4-negative
subjects (Morris et al. 2002). However, in the Honolulu
Asia Aging Study it was found that vitamin E and C sup-
plements appear to protect against vascular dementia and
improve cognitive function in later life (Masaki et al.
2000), although midlife dietary intake of antioxidants has
no apparent effect on dementia in later life (Laurin et al.
2002). In the Nurses’ Health Study vitamin E supplements
but not vitamin C supplements were found to be related to
modest cognitive benefits in older women (Grodstein et al.
2003), while in the Cache County Study vitamin E and C
supplements in combination were reported to reduce the
prevalence and incidence of AD (Zandi et al. 2004).
A widely published but controversial study relating to
the mechanism of action of extremely high doses of
vitamin E (2000 mg/d) in patients with AD suggests that
such levels can lead to a delay in institutionalization (Sano
et al. 1997). The French Paquid Study has demonstrated
that high flavonoid intake is associated with a reduction in
risk of dementia to a relative risk of 0.49 (Commenges
et al. 2000), and in the SENECA Study (Haller et al. 1996)
cross-sectional analysis (Table 1) has shown a consistent
and significant, albeit weak, correlation between memory
performance and plasma concentrations of carotenoids,
folate (P<0.05) and a-tocopherol (P<0.05).
An important point remains that although higher vitamin
C intake predicts better memory function, factors such as
education are far more important than differences in
micronutrient intakes (Perrig et al. 1997; Fig. 2). The epi-
demiological findings to some extent contradict the vast
amount of experimental work in cell culture, and in trans-
genic models of AD in which bioactive antioxidant com-
pounds show a profound effect on markers of AD and
behaviour. Thus, numerous phenolic substances have been
shown to be protective (Joseph et al. 1998a,b, 2005),
probably by affecting Ca homeostasis in neuronal cells
(Joseph et al. 2004).
Metals, oxidative stress and Altzheimer’s disease
Copper and zinc
Of particular interest is the role of metals. The interaction
between Fe, Cu and Zn, and also Al and other metals
(e.g. Hg, As etc.), and amyloid and the amyloid-b (abeta)
fragment of the APP molecule is complex and may depend
on cholesterol metabolism (House et al. 2004; Fisher &
Naughton, 2005; Maynard et al. 2005; Valko et al. 2005).
APP has Cu-binding sites and experimental findings
(Maynard et al. 2005) indicate that a high Cu content sta-
bilizes APP. The function of APP is still largely unknown,
but one of the possible functions might be the regulation of
metal homeostasis (Fisher & Naughton, 2005). Low Cu
levels actually increase amyloid and abeta concentrations
and high Cu levels stabilize APP. Increasing brain Cu
availability decreases levels of abeta and amyloid plaque
formation. Lowering Cu concentrations leads to a down-
regulation of the transcription of APP (Maynard et al.
2005).
APP is catabolized either by a-secretase and subse-
quently by g-secretase leading to non-toxic fragments or, if
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Fig. 2. Semantic memory in 380 subjects from the prospective
Basel Study subdivided into young–old (65–74 years) and old–old
(‡75 years) groups with low (K) and high (_) plasma vitamin C
(50th percentile as a cut off), assessed from 1971 to 1973 and
cognitively assessed in 1993. The effect of vitamin C on memory
performance is present in all groups independent of education
(From Perrig et al. 1997).
Table 1. Memory performance, as assessed by mini mental status
examination, and its correlation with plasma micronutrient levels;
results of the SENECA Study (Haller et al. 1996)
Micronutrient r * P
a-Carotene 0.11 <0.001
b-Carotene 0.09 <0.05
Lycopene 0.17 <0.001
b-Cryptoxanthene 0.19 <0.001
a-Tocopherol 0.16 <0.001
Folate 0.10 <0.05
Cobalamine 0.13 <0.001
*The cross-sectional analysis of the SENECA cohort reveals significant, albeit
weak, correlations between plasma antioxidant micronutrients and memory
performance.
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internalized in the endoplasmic reticulum and Golgi appa-
ratus, by b-secretase and g-secretase. The resulting abeta
fragment is a key pathogenic intermediate in AD (Love-
stone & McLoughlin, 2002; Selkoe & Schenk, 2002).
Hence, APP is a large membrane-bound Cu-binding pro-
tein that is essential in maintaining synaptic function. Both
APP and abeta oxidize cholesterol, requiring Cu. Oxycho-
lesterol inhibits a-secretase but not b-secretase, thus
accelerating abeta production. Furthermore, oxycholesterol
has a 200-fold higher affinity to abeta than to APP. Thus,
at a given point Cu may become a powerful enhancer of
reactive oxygen species formation and the APP stabilizing
effect will be lost (Nelson & Alkon, 2005).
A fascinating hypothesis emerges from experiments with
transgenic animals in which a diet deficient in n-3 fatty
acids perinatally up regulates Zn transport proteins in the
brain that remain up regulated into adulthood, leading to a
Zn overload in the brain and displacement of Cu from APP
binding sites, thus favouring abeta formation (Jayasooriya
et al. 2005).
Iron, aluminium, selenium and mercury
Fe and Al co-localize with abeta plaques (Exley, 2005).
High cholesterol levels are thought to be a risk factor for
AD (Engelhart et al. 2002a), but as a single factor they are
probably of minor importance (Hofman et al. 1997);
however, together with a high Fe load the risk is markedly
elevated. The National Health and Nutrition Examination
Survey I 18-year follow-up (n > 6500) has found that the
risk ratio for developing AD is 3.19 (95% CI 1.31, 7.75)
when both transferrin saturation and cholesterol are above
the 75th percentile (Mainous et al. 2005).
Levels of advanced glycation end products and lipid
peroxidation products in the brain, cerebrospinal fluid and
plasma of patients with AD are potentiated by Al and Fe
(House et al. 2004).
Al affects neuronal structures (synapses etc.; Jing et al.
2004), and chronic exposure to Al in drinking water
increases inflammatory variables selectively in the brain
(Campbell et al. 2004), while presenilin 2 production
(aberrant splicing isoform, a diagnostic feature of sporadic
AD) induced by hypoxia is accelerated by chronic Al
exposure (Matsuzaki et al. 2004).
Despite the importance of Se as an antioxidant and
key trace element for antioxidant enzymes there is little
information relating to Se and AD (Cornett et al. 1998;
Meseguer et al. 1999; Tabet et al. 2001; Chen & Berry,
2003). Of interest is the interaction between Se and Hg.
Uptake of Hg into cells may be effected by the same
transport mechanisms as Se uptake (Bridges & Zalups,
2005). Thus, in theory low Se levels in food may expose
cells to higher Hg loads. The formation of a Hg–Se com-
plex seems to be protective, as is suggested by findings in
marine animals (Endo et al. 2002) and in cell cultures
(Frisk et al. 2003). A relationship between Hg exposure
(e.g. by dental fillings) and AD (Fung et al. 1997) has not
(Fung et al. 1997) been established, even though a corre-
lation has been shown between Hg concentration and Fe
(Barany et al. 2005) and dental fillings (Fung et al. 1997;
Barany et al. 2003).
Conclusions
The uniform single exponential increase with age of
dementia and AD, with comparable rates in many socio-
culturally-different societies, indicate that endogenous
genetic–metabolic factors are prominent. Nevertheless,
micronutrients may affect the rate of disease via protection
against reactive oxygen species, directly as antioxidants or
indirectly by stabilizing sensitive structures or improving
metabolism. The effect of pro-oxidant nutrients, on the
other hand, may catalyse the development of disease by
interaction with proteins and lipids involved in the patho-
physiology of AD and other neurodegenerative disorders.
Based on these premises the impact of micronutrients is
most effective if present over a long period during the
lifetime, while interventions later in the disease process are
of minor effectiveness (Launer & Kalmijn, 1998; Tabet
et al. 2001). Of potentially far-reaching consequences is
the concept that nutritional conditions in early life may
programme metabolic functions, leading over time to an
increasing imbalance and thus favouring the emergence of
diseases states. A macronutrient and micronutrient intake
that has preventive effects against CVD is most likely also
to be effective against neurodegenerative disorders.
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